Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to the Broad Institute of Massachusetts Institute of Technology, not the University of California, Berkeley.
Moderna is facing additional challenges to patent the COVID-19 vaccine Spikevax, as Arbutus Biopharma and Genevant filed a lawsuit against the company challenging patent infringement.
Chicago-based AbbVie has been making major decisions with company-wide impacts that could benefit its bottom line.
The U.S. health regulator approved the first generic version of AbbVie Inc.’s Restasis, a treatment used in increasing tear production in patients with dry-eye syndrome.
Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.
Novartis AG said on January 4 a U.S. court of appeals upheld the validity of a dosage regimen patent for the company’s multiple sclerosis treatment Gilenya, allowing a permanent injunction against Chinese generic drugmaker HEC Pharma to stay in place until the patent expires in 2027.
Moderna’s legal battle over who deserves credit for a crucial part of its OVID-19 vaccine was put on hold after the company abandoned the key patent application, a filing that could affect Moderna’s future distribution and profits. The company decided to drop the patent application to “allow more time for discussions with the NIH,” which will be aimed at an amicable resolution.
U.S. National Institutes of Health scientists played “a major role” in developing Moderna Inc.’s Covid-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH Director Dr. Francis Collins told Reuters on November 10.
A consumer rights advocacy group is crying foul over Moderna’s omission of government scientists in some credits for the company’s Covid-19 vaccine patent application. Moderna and scientists from the National Institutes of Health (NIH) worked together to develop the company’s mRNA vaccine against SARS-CoV-2.
